{"id":"argx-117","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARGX-117 works by binding to CD70, a protein involved in the activation of immune cells. This binding leads to the depletion of CD70-expressing immune cells, which are thought to contribute to autoimmune diseases. By reducing the activity of these cells, ARGX-117 aims to alleviate symptoms and slow disease progression.","oneSentence":"ARGX-117 is a monoclonal antibody targeting CD70.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:04.396Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of generalized myasthenia gravis"}]},"trialDetails":[{"nctId":"NCT05907096","phase":"PHASE2","title":"ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-02-17","conditions":"Delayed Graft Function","enrollment":103},{"nctId":"NCT05405361","phase":"PHASE2","title":"A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2023-01-18","conditions":"Multifocal Motor Neuropathy (MMN)","enrollment":51},{"nctId":"NCT06284954","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"argenx","startDate":"2024-08-20","conditions":"Dermatomyositis, Myositis","enrollment":3},{"nctId":"NCT05225675","phase":"PHASE2","title":"A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy","status":"COMPLETED","sponsor":"argenx","startDate":"2022-03-31","conditions":"Multifocal Motor Neuropathy","enrollment":54},{"nctId":"NCT04532125","phase":"PHASE1","title":"SAD and MAD Study With IV and SC Doses of ARGX-117","status":"COMPLETED","sponsor":"argenx","startDate":"2020-08-03","conditions":"Healthy Volunteers","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARGX-117","genericName":"ARGX-117","companyName":"argenx","companyId":"argenx","modality":"Biologic","firstApprovalDate":"","aiSummary":"ARGX-117 is a monoclonal antibody targeting CD70. Used for Treatment of generalized myasthenia gravis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}